These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 38361435)

  • 1. Nanomedicine Tumor Targeting.
    Lammers T
    Adv Mater; 2024 Jun; 36(26):e2312169. PubMed ID: 38361435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-targeted nanomedicines for cancer theranostics.
    Arranja AG; Pathak V; Lammers T; Shi Y
    Pharmacol Res; 2017 Jan; 115():87-95. PubMed ID: 27865762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining Nanomedicine and Immunotherapy.
    Shi Y; Lammers T
    Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenging the fundamental conjectures in nanoparticle drug delivery for chemotherapy treatment of solid cancers.
    Yang J; Wang X; Wang B; Park K; Wooley K; Zhang S
    Adv Drug Deliv Rev; 2022 Nov; 190():114525. PubMed ID: 36100142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors Influencing the Delivery Efficiency of Cancer Nanomedicines.
    Ullah R; Wazir J; Khan FU; Diallo MT; Ihsan AU; Mikrani R; Aquib M; Zhou X
    AAPS PharmSciTech; 2020 May; 21(4):132. PubMed ID: 32409932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanomedicines for cancer therapy: current status, challenges and future prospects.
    Bor G; Mat Azmi ID; Yaghmur A
    Ther Deliv; 2019 Feb; 10(2):113-132. PubMed ID: 30678550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological and physical vessel modulation strategies to improve EPR-mediated drug targeting to tumors.
    Ojha T; Pathak V; Shi Y; Hennink WE; Moonen CTW; Storm G; Kiessling F; Lammers T
    Adv Drug Deliv Rev; 2017 Sep; 119():44-60. PubMed ID: 28697952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reappraisal of anticancer nanomedicine design criteria in three types of preclinical cancer models for better clinical translation.
    Luan X; Yuan H; Song Y; Hu H; Wen B; He M; Zhang H; Li Y; Li F; Shu P; Burnett JP; Truchan N; Palmisano M; Pai MP; Zhou S; Gao W; Sun D
    Biomaterials; 2021 Aug; 275():120910. PubMed ID: 34144373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current understandings and clinical translation of nanomedicines for breast cancer therapy.
    Jiang Y; Jiang Z; Wang M; Ma L
    Adv Drug Deliv Rev; 2022 Jan; 180():114034. PubMed ID: 34736986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New Strategies in Cancer Nanomedicine.
    Tong R; Kohane DS
    Annu Rev Pharmacol Toxicol; 2016; 56():41-57. PubMed ID: 26514197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent Advances in Targeted Tumor Chemotherapy Based on Smart Nanomedicines.
    Qin SY; Zhang AQ; Zhang XZ
    Small; 2018 Nov; 14(45):e1802417. PubMed ID: 30247806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survey of Clinical Translation of Cancer Nanomedicines-Lessons Learned from Successes and Failures.
    He H; Liu L; Morin EE; Liu M; Schwendeman A
    Acc Chem Res; 2019 Sep; 52(9):2445-2461. PubMed ID: 31424909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent Progress and Challenges in Clinical Translation of Nanomedicines in Diagnosis and Treatment of Lung Cancer.
    Yadav B; Chauhan M; Singh RP; Sonali ; Shekhar S
    Curr Drug Targets; 2024; 25(1):12-24. PubMed ID: 38058096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating Nanomedicines: Obstacles and Advancements.
    Swierczewska M; Crist RM; McNeil SE
    Methods Mol Biol; 2018; 1682():3-16. PubMed ID: 29039088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-Targeting Glycol Chitosan Nanoparticles for Cancer Heterogeneity.
    Ryu JH; Yoon HY; Sun IC; Kwon IC; Kim K
    Adv Mater; 2020 Dec; 32(51):e2002197. PubMed ID: 33051905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanomedicines based drug delivery systems for anti-cancer targeting and treatment.
    Jain V; Jain S; Mahajan SC
    Curr Drug Deliv; 2015; 12(2):177-91. PubMed ID: 25146439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanomedicines for developing cancer nanotherapeutics: from benchtop to bedside and beyond.
    Iqbal J; Abbasi BA; Ahmad R; Mahmood T; Ali B; Khalil AT; Kanwal S; Shah SA; Alam MM; Badshah H; Munir A
    Appl Microbiol Biotechnol; 2018 Nov; 102(22):9449-9470. PubMed ID: 30219952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer Nanomedicines Based on Synthetic Polypeptides.
    Sun H; Gu X; Zhang Q; Xu H; Zhong Z; Deng C
    Biomacromolecules; 2019 Dec; 20(12):4299-4311. PubMed ID: 31659901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting Nanomedicines to Prostate Cancer: Evaluation of Specificity of Ligands to Two Different Receptors In Vivo.
    Pearce AK; Fuchs AV; Fletcher NL; Thurecht KJ
    Pharm Res; 2016 Oct; 33(10):2388-99. PubMed ID: 27225496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted nanomedicine in cisplatin-based cancer therapeutics.
    Han Y; Wen P; Li J; Kataoka K
    J Control Release; 2022 May; 345():709-720. PubMed ID: 35367476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.